295 related articles for article (PubMed ID: 36336887)
1. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway.
Cui S
J Clin Lab Anal; 2022 Dec; 36(12):e24761. PubMed ID: 36336887
[TBL] [Abstract][Full Text] [Related]
2. [Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of
m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of
Lung Cancer].
Zhang Y; Wang Y; Liu M
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):919-933. PubMed ID: 38163978
[TBL] [Abstract][Full Text] [Related]
3. Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (
Zhou Y; Li J; Yang X; Song Y; Li H
Bioengineered; 2021 Dec; 12(2):12003-12022. PubMed ID: 34787052
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1.
Wang J; Ding W; Xu Y; Tao E; Mo M; Xu W; Cai X; Chen X; Yuan J; Wu X
Aging (Albany NY); 2020 Mar; 12(5):4558-4572. PubMed ID: 32163372
[TBL] [Abstract][Full Text] [Related]
5. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway.
Ma X; Ren H; Zhang Y; Wang B; Ma H
Environ Toxicol; 2022 Dec; 37(12):3013-3027. PubMed ID: 36125241
[TBL] [Abstract][Full Text] [Related]
6. LncRNA PSMA3-AS1 promotes cell proliferation, migration, and invasion in ovarian cancer by activating the PI3K/Akt pathway via the miR-378a-3p/GALNT3 axis.
Xu Z; Jin H; Duan X; Liu H; Zhao X; Fan S; Wang Y; Yao T
Environ Toxicol; 2021 Dec; 36(12):2562-2577. PubMed ID: 34520102
[TBL] [Abstract][Full Text] [Related]
7. METTL3-Mediated m
Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
[TBL] [Abstract][Full Text] [Related]
8. Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Li H; Zhou Y; Cheng H; Tian J; Yang S
Exp Mol Pathol; 2020 Aug; 115():104481. PubMed ID: 32497621
[TBL] [Abstract][Full Text] [Related]
9. M
Chen JQ; Tao YP; Hong YG; Li HF; Huang ZP; Xu XF; Zheng H; Hu LK
Cell Cycle; 2021 Dec; 20(23):2507-2518. PubMed ID: 34658294
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F
J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308
[TBL] [Abstract][Full Text] [Related]
11. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Bi X; Lv X; Liu D; Guo H; Yao G; Wang L; Liang X; Yang Y
Cancer Gene Ther; 2021 Apr; 28(3-4):335-349. PubMed ID: 32939058
[TBL] [Abstract][Full Text] [Related]
12. The N
Li B; Zhao R; Qiu W; Pan Z; Zhao S; Qi Y; Qiu J; Zhang S; Guo Q; Fan Y; Xu H; Li M; Li G; Xue H
Theranostics; 2022; 12(14):6363-6379. PubMed ID: 36168628
[No Abstract] [Full Text] [Related]
13. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
14. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
15. lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus.
Liu HT; Zou YX; Zhu WJ; Sen-Liu ; Zhang GH; Ma RR; Guo XY; Gao P
Cell Death Differ; 2022 Mar; 29(3):627-641. PubMed ID: 34608273
[TBL] [Abstract][Full Text] [Related]
16. METTL3-mediated m6A modification of EPPK1 to promote the development of esophageal cancer through regulating the PI3K/AKT pathway.
Jia J; Yu L
Environ Toxicol; 2024 May; 39(5):2830-2841. PubMed ID: 38293837
[TBL] [Abstract][Full Text] [Related]
17. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
[TBL] [Abstract][Full Text] [Related]
18. LncRNA RHPN1-AS1 promoted cell proliferation, invasion and migration in cervical cancer via the modulation of miR-299-3p/FGF2 axis.
Duan H; Li X; Chen Y; Wang Y; Li Z
Life Sci; 2019 Dec; 239():116856. PubMed ID: 31525429
[TBL] [Abstract][Full Text] [Related]
19. YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis.
Zhu J; Tong H; Sun Y; Li T; Yang G; He W
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108067
[TBL] [Abstract][Full Text] [Related]
20. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
Hussain SA; Venkatesh T
Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
